Four patients with clear cell gynecologic cancer responded; all four responses were ongoing at cutoff.
MacroGenics (MGNX) reported positive interim Phase 2 data for lorigerlimab in clear cell gynecologic cancer (CCGC), showing a 25% ORR and 44% DCR. The safety profile was manageable. The company is enrolling more patients and expects updated results in 2027.
How this was made
The 30-second read
Why it matters
The disclosed interim efficacy (confirmed ORR 25%, DCR 44%) and manageable safety profile are supportive for the program, while the planned expansion at a lower dose and the next major readout in first half of 2027 create a clear forward timeline for reassessment.
Market read
Traders can reassess clinical probability of success and near-term sentiment for MGNX based on newly presented interim response metrics and the shift to a lower dose cohort.
What to watch
The article emphasizes dose optimization (3 mg/kg Q3W) and additional enrollment, so near-term valuation may hinge on whether efficacy holds at the lower dose and whether safety remains manageable with more patients.
Background
MacroGenics is running the Phase 2 LINNET study of lorigerlimab (PD-1/CTLA-4 bispecific DART) in advanced gynecologic cancers, including clear cell gynecologic cancer.
Ticker impact
MacroGenics reported interim Phase 2 LINNET data for lorigerlimab in clear cell gynecologic cancer, including confirmed ORR 25% and DCR 44%.
Likely upward pressure as investors price improved clinical prospects, tempered by the interim nature and upcoming 2027 updates.
The article discloses new interim clinical results presented at ESMO and includes response metrics plus a planned dose reduction and additional enrollment, which are decision-relevant for development expectations.
Market effects
Adds incremental evidence for PD-1/CTLA-4 dual blockade approaches in rare, platinum-resistant gynecologic cancers.
Limited direct impact beyond US-listed biotech sentiment.
ESMO-congress disclosure can influence global oncology trial expectations and peer read-through.
Counterpoint
Interim results in a small subset can overstate durability and generalizability; investors may fade the move until updated LINNET data and longer follow-up.
Key entities
- companyMacroGenics, Inc.
Sponsor of the Phase 2 LINNET study evaluating lorigerlimab in clear cell gynecologic cancer.
- druglorigerlimab
Investigational PD-1/CTLA-4 bispecific DART molecule being tested as single agent in LINNET.
- clinical_trialLINNET Phase 2 study
Phase 2 trial evaluating lorigerlimab in PROC and CCGC; primary endpoint is ORR.
- eventESMO 2026 Congress
Conference where the interim data were presented on Oct. 26, 2026.
